RESUMEN
Bladder cancer is the second most common urological malignant disease. There are various treatment strategies which, depending on tumor stage and grade, can minimize recurrence and lower progression rate. Alternative treatment modalities of instillation therapy after failure with first line Mitomycin C or BCG do exist and have become a point of interest, especially in times of shortage of agents such as BCG.This article aims to give an overview of the current existing thermotherapeutic treatment options (electroinductive and electroconductive). The article starts with the first publication presenting thermochemotherapy with Mitomycin C using the Synergo ® device and highlights the first randomized controlled study comparing Mitomycin C (Synergo ® ) with conventional BCG therapy. The article also presents data about first conductive Mitomycin C therapy using the new Combat ® and the Unithermia ® device.Finally, it discusses in which cases thermotherapy with Mitomycin C can be applied safely based upon the current available data.